Using Mobile Technology to Reduce Stress in Caregivers of Persons with Dementia. A Scalable Solution to A Growing Problem

项目总结： 使用NIA 2年R21赠款机制，拟议的研究将审查可行性(可接受性标记 和需求)，以及基于消费者的移动正念应用在减少压力中平静的概念证明， 不同地理位置的不同压力照顾者的情绪困扰和睡眠障碍 阿德勒。平静教授正念的基本原理，并使用基于证据的行为原则让照顾者参与到 持续练习(&gt；10分钟/天)，在他们方便的时候投入最少的时间，而不需要 旅行或训练有素的提供者。为了达到我们的目标，我们将进行单盲、试点、可行性、概念验证 平静的RCT(12周，每天10分钟练习)与注意力安慰剂时间和剂量匹配的播客 对照组(POD；12周，&gt；每天10分钟)。评估将在基线、计划后(12周)进行 之后)和20周的随访期。照顾者还将完成每周的评估。我们的团队已经做好了充分准备 使用移动应用程序的特定经验进行这项研究，包括CAME、干预开发、 可行性测试和临床试验；ADRD护理员；招募国家和地区不同的样本；R21赠款 提案。在R21的两年期结束时，我们将有明确的证据证明研究程序的可行性， 随机性、可接受性、可信度、坚持性、留住和招募能力及其在减少风险中的概念证明 ADRD患者照顾者的压力。这项R21研究的结果将被用来申请资金，以进行全面的 动力功效RCT，如果通过R01达到设定的基准(见研究战略中的表)。我们的目标是 传播和实施平静，以减少所有人的压力、情绪障碍和睡眠困难 ADRD患者的照顾者。

PROJECT SUMMARY: Using the NIA 2 year R21 grant mechanisms, the proposed study will examine the feasibility (markers of acceptability and demand), and proof of concept of the consumer based mobile mindfulness application Calm in decreasing stress, emotional distress and sleep dysfunction in heterogeneous, geographically diverse, stress caregivers of individuals with ADRD. Calm teaches fundamentals of mindfulness and uses evidence based behavioral principles to engage caregivers in sustained practice (>10 min/day) with minimal time commitment, when it is convenient for them, without the need of travel or of a trained provider. To achieve our aims, we will conduct a single blind, pilot, feasibility, proof of concept RCT of CALM (12 weeks, > 10 minutes daily practice) versus an attention placebo time and dose matched podcast control (POD; 12 weeks, >10 minutes daily listening). Assessments will be conducted at baseline, post program (12 weeks later) and at 20 weeks follow-up. Caregivers will also complete weekly assessments. Our team is well positioned to conduct this study with specific experience with mobile applications including Calm; intervention development, feasibility testing and clinical trials; ADRD caregivers; recruitment of national, geographically diverse samples; R21 grant proposals. At the end of the 2-year period of this R21 we will have clear evidence of the feasibility of study procedures, randomization, acceptability, credibility, adherence, ability to retain and recruit as well as its proof of concepts in reducing stress in caregivers of people with ADRD. Results from this R21 study will be used to apply for funding to conduct a fully powered efficacy RCT, if set benchmarks are met (see Table in the Research Strategy), through an R01. The goal is dissemination and implementation of Calm to reduce stress, emotional dysfunction, and sleep difficulties among all caregivers of individuals with ADRD.